Cardiomyopathy Forum-1
|
13:30-15:30
|
|---|
| 主持 Moderators | Takafumi TSUJI, 黎励文 Liwen LI, 蒋学俊 Xuejun JIANG, 罗素新 Suxin LUO, 贺永明 Yongming HE | ||
| 讨论嘉宾 Discussants | 姜萌 Meng JIANG, 陈艺莉 Yili CHEN, 刘莹 Ying LIU | ||
|
13:30-13:50 |
Overture研究解读（中外ATTR-CM临床表型差异分析） Overture Study Insights: Analysis of Clinical Phenotypic Differences in ATTR-CM Between Asian and International Cohorts |
张抒扬 Shuyang ZHANG | |
|
13:50-14:10 |
2025年欧洲心脏病学会(ESC)大会肥厚型心肌病前沿进展速递 2025 European Society of Cardiology (ESC) Congress: Frontline Advances in Hypertrophic Cardiomyopathy - A Rapid Update 解析： |
康连鸣 Lianming KANG | |
|
14:10-14:30 |
Fabry诊断治疗经验分享 Sharing Experiences in the Diagnosis and Treatment of Fabry Disease |
Geu-Ru HONG | |
|
14:30-14:50 |
Insights and Consensus about Fabry Disease in Taiwan, China | Chung-Lieh HUNG | |
|
14:50-15:10 |
多模态影像技术用于心肌病诊断和评估 Multimodal Imaging in the Diagnosis and Assessment of Cardiomyopathy |
陈玉成 Yucheng CHEN | |
|
15:10-15:30 |
讨论 | ||
Cardiomyopathy Forum-2
|
15:30-17:30
|
|---|
| 主持 Moderators | 柏勇平 Yongping BAI, 孔洪 Hong KONG, 张冬颖 Dongying ZHANG, 潘小宏 Xiaohong PAN | ||
| 讨论嘉宾 Discussants | 朴哲浩 Zhehao PIAO, 谢小洁 Xiaojie XIE, 王珍珍 Zhenzhen WANG | ||
|
15:30-15:50 |
ATTR-CM系统性管理的必要性 The Necessity of Systemic Management for ATTR-CM |
彭道泉 Daoquan PENG | |
|
15:50-16:10 |
肥厚型心肌病诊疗新进展及突破 Recent Advances and Breakthroughs in HCM Management |
陆士娟 Shijuan LU | |
|
16:10-16:30 |
Cardiac Myosin Inhibitor in Obstructive Hypertrophic Cardiomyopathy: Real World Experience | Hyung-Kwan KIM | |
|
16:30-16:50 |
What’s New ?ATTR 最新诊疗进展 What’s New in ATTR diagnosis and Treatment ? |
董建增 Jianzeng DONG | |
|
16:50-17:10 |
德国心肌淀粉样变中心建设分享 Establishment of the BerlinCardiac Amyloidosis Centre:Sharing the Experience |
Fabian KNEBEL | |
|
17:10-17:30 |
讨论 Discussion |
||
Lipid Forum-4 ASCVD治疗新进展
|
10:00-12:00
|
|---|
| 主持 Moderators | 李建平 Jianping LI, 傅国胜 Guosheng FU | ||
| 特邀嘉宾 Invited Guests | 王建安 Jianan WANG | ||
| 讨论嘉宾 Discussants | 叶涛 Tao YE, 董樑 Liang DONG, 胡涛 Tao HU | ||
|
10:00-10:05 |
开场致辞 Opening Remarks |
||
|
10:05-10:35 |
《高血压患者靶器官动态评估与长程管理专家共识》解读 Interpretation of the Expert Consensus on Ongoing Target Organ Evaluation and Longitudinal Management of Hypertension |
陶军 Jun TAO | |
|
10:35-11:05 |
双料印证，降脂破局：从RCT到RWS的双料冠军 Bridging RCT to RWS: The Validated Efficacy of a Leading Lipid-Lowering Therapy |
张毅 Yi ZHANG | |
|
11:05-11:25 |
从“强效降脂”到“持久达标”： ACS到CCS血脂管理新策略 From Potent Reduction to Sustained Goals: Novel Lipid Management Strategies Across the ACS-CCS Spectrum |
曹乾 Qian CAO | |
|
11:25-11:55 |
大咖论道 Expert Discussion |
||
|
11:55-12:00 |
总结 Discussion |
||
Coronary Physiology Symposium
|
13:30-15:30
|
|---|
| 主持 Moderators | 钱菊英 Juying QIAN, 刘斌 Bin LIU, 杨伟宪 Weixian YANG, 高海 Hai GAO | ||
| 讨论嘉宾 Discussants | 丁风华 Fenghua DING, 王永祥 Yongxiang WANG, 金元哲 Yuanzhe JIN, 王敬萍 Jingping WANG | ||
|
13:30-13:35 |
嘉宾致辞 Guest Speech |
定 待 | |
|
13:35-13:55 |
“融合无界”冠脉影像新功能及技术介绍 “Fusion Pilot” Coronary Imaging New Function & Technology Introduction |
涂圣贤 Shengxian TU | |
|
13:55-14:10 |
“融合无界”功能及影像技术——多模态QFR发布仪式 “Boundless Integration” Function and Imaging Technology — Multimodal QFR Launch Ceremony |
||
|
14:10-14:30 |
“融合无界”新技术冠脉复杂病变临床应用 Clinical Application of the “Boundless Integration” New Technology in Complex Coronary Lesions |
蒋峻 Jun JIANG | |
|
14:30-14:50 |
“融合无界”新技术冠脉分叉病变临床应用 Clinical Application of the “Boundless Integration” New Technology in Coronary Bifurcation Lesions |
宋雷 Lei SONG | |
|
14:50-15:10 |
“融合无界”新技术冠脉CTO病变临床应用 Clinical Application of the “Boundless Integration” New Technology in Coronary CTO Lesions |
鄢华 Hua YAN | |
|
15:10-15:30 |
讨论 Discussion |
||
Metabolic & CVD Forum-3
|
15:30-17:30
|
|---|
| 主持 Moderators | 蒋峻 Jun JIANG, 何红 Hong HE | ||
|
15:30-15:50 |
高血压合并肥胖患者，长期体重管理势在必行 Long-Term Weight Management is Imperative for Hypertensive Patients with Obesity |
高秀芳 Xiufang GAO | |
|
15:50-16:10 |
肥胖合并ASCVD减重助益疾病综合管理 Weight Management Improves Clinical Outcome of Obesity &ASCVD Comorbidity |
金剑虹 Jianhong JIN | |
|
16:10-16:30 |
穆峰达在T2DM多维度血糖管理中的优势 The superiority of Mounjaro in T2DM Management |
郑超 Chao ZHENG | |
|
16:30-16:50 |
从药物机制出发谈替尔泊肽消除异位脂肪沉积 Discussion on Tirzepatide Eliminating Ectopic Fat Deposition from the Perspective of Drug Mechanism |
刘治军 Zhijun LIU | |
|
16:50-17:10 |
成人肥胖合并血脂异常病例管理 Case Sharing |
杨莹 Ying YANG | |
|
17:10-17:30 |
讨论 Discussion |
||
Cardiomyopathy Forum-4 指南速递
|
08:00-10:00
|
|---|
| 主持 Moderators | 李新立 Xinli LI, 项美香 Meixiang XIANG, 袁璟 Jing YUAN, 马为 Wei MA, 朱敏 Min ZHU | ||
|
08:00-08:20 |
《中国心肌病综合管理指南2025》——精准医学理念指导心肌病临床实践 “Chinese Guidelines for Comprehensive Management of Cardiomyopathy 2025” - Clinical Practice of Cardiomyopathy Guided by Precision Medicine Concept |
宋雷 Lei SONG | |
|
08:20-08:40 |
县域心肌病合理用药与综合管理指南 Guidelines for Rational Drug Use and Comprehensive Management of Cardiomyopathy in County-Level Hospitals |
邹玉宝 Yubao ZOU | |
|
08:40-09:00 |
从《2025 ESC心肌炎和心包炎》指南看心肌炎诊疗证据更新 Update of Myocarditis Diagnosis and Treatment Evidence from the “2025 ESC Myocarditis and Pericarditis” Guidelines |
陈瑞珍 Ruizhen CHEN | |
|
09:00-09:20 |
代谢性心肌病的诊疗原则 Diagnostic and Therapeutic Principles of Metabolic Cardiomyopathy |
金玮 Wei JIN | |
|
09:20-09:40 |
ATTR-CM的精准诊疗和多维度破局之道 Precision Diagnosis and Treatment of ATTR-CM and Multi-Dimensional Breakthrough Approaches |
罗素新 Suxin LUO | |
|
09:40-10:00 |
《心肌病心内膜心肌活检及病理检查临床应用指南》解读 Interpretation of the “Guidelines for Clinical Application of Endomyocardial Biopsy and Pathological Examination in Cardiomyopathy” |
李莉 Li LI | |
Cardiomyopathy Forum-5 临床前沿
|
10:00-12:00
|
|---|
| 主持 Moderators | 毛威 Wei MAO, 肖红艳 Hongyan XIAO, 郑泽琪 Zeqi ZHENG, 吕玲春 Lingchun LV | ||
|
10:00-10:20 |
国家创新1.1新药物：HRS-1893的安全性及药代动力学研究结果 National Innovative 1.1 New Drug: Safety and Pharmacokinetic Research Results of HRS-1893 |
康连鸣 Lianming KANG | |
|
10:20-10:40 |
非缺血性扩张型心肌病患者猝死风险评估新方案（Radiology） New Scheme for Sudden Cardiac Death Risk Assessment in Patients with Non-Ischemic Dilated Cardiomyopathy (Radiology) |
陆敏杰 Minjie LU | |
|
10:40-11:00 |
微创室间隔电切术（MESM）治疗梗阻性肥厚型心肌病 Minimally Invasive Ventricular Septal Electrocision (MESM) for Obstructive Hypertrophic Cardiomyopathy |
崔勇 Yong CUI | |
|
11:00-11:20 |
2024年心肌病年报与质控报告解读 Interpretation of the 2024 Cardiomyopathy Annual Report and Quality Control Report |
许连军 Lianjun XU | |
|
11:20-11:40 |
应用心肌肌球蛋白抑制剂对中国梗阻性肥厚型心肌病患者磁共振特征的影响（JACC：ASIA） （JACC：ASIA）：Effect of Myocardial Myosin Inhibitor Application on Magnetic Resonance Features in Chinese Patients with Obstructive Hypertrophic Cardiomyopathy (JACC: ASIA) |
田庄 Zhuang TIAN | |
|
11:40-12:00 |
讨论 Discussion |
||